MONTREAL, June 5 /PRNewswire-FirstCall/ -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announced today that the official signing ceremony for the strategic alliance concluded earlier this year with the Wuhan Institute of Biological Products ("WIBP") a subsidiary of China National Biotec Group ("CNBG") was held on Wednesday, June 4, 2008 at CNBG's Beijing location.
Present at the signing were CNBG's President and Chief Executive Officer Ms. Lifeng Wang, WIBP's Director Dr. Xiaoming Yang, ProMetic's President and Chief Executive Officer Mr. Pierre Laurin as well as several officials from the CNBG and WIBP organizations. Additional information is available on CNBG's web site at http://www.cnbgint.com and on WIBP's web site at http://www.wibp.com.cn/en.
More about Wuhan Institute of Biological Products
WIBP (http://www.wibp.com.cn or http://www.wibp.com.cn/en), located in Wuhan, China. is one of the subsidiaries of CNBG, has over 50 years experience in the fields of biomedical research and product development; historically strong in R&D, WIBP is the only institute certified by state to offer doctoral program among six Institute of Biological Products in CNBG. Today, WIBP has more than 1,000 employees, and major products include two dozen vaccines and plasma derivatives currently marketed throughout the China.
More about China National Biotec Group
CNBG (http://www.cnbgint.com or http://www.cnbg.com.cn), headquartered in Beijing,
China, is a state-owned enterprise and the largest biotech company in China
dedicated to discover, develop, manufacture and market a broad range of
human health products, including vaccines
|SOURCE ProMetic Life Sciences Inc.|
Copyright©2008 PR Newswire.
All rights reserved